- Home
- GRRR vs XFOR Comparison
GRRR vs XFOR Comparison
Compare GRRR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRRR | XFOR |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.0M | 323.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GRRR | XFOR |
|---|---|---|
| Price | $12.84 | $3.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | ★ 1.0M | 375.5K |
| Earning Date | 03-30-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,747,682.00 | $33,979,000.00 |
| Revenue This Year | $36.15 | $1,266.01 |
| Revenue Next Year | $68.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 47.86 | ★ 2925.74 |
| 52 Week Low | $10.49 | $1.35 |
| 52 Week High | $44.15 | $16.29 |
Technical Indicators
Market Signals| Indicator | GRRR | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 46.89 |
| Support Level | $10.49 | $3.52 |
| Resistance Level | $16.05 | $3.74 |
| Average True Range (ATR) | 1.16 | 0.18 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 42.27 | 33.33 |
Price Performance
Historical ComparisonAbout GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.